Ovid Therapeutics Inc. (OVID)

US — Healthcare Sector
Peers: CTMX  SPRO  NLTX  TIL  NXTC  ASMB  ACHL  NUVB  CNTB 

Automate Your Wheel Strategy on OVID

With Tiblio's Option Bot, you can configure your own wheel strategy including OVID - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OVID
  • Rev/Share 0.0044
  • Book/Share 0.4742
  • PB 0.6145
  • Debt/Equity 0.0229
  • CurrentRatio 4.934
  • ROIC -0.7735

 

  • MktCap 20721308.0
  • FreeCF/Share -0.3966
  • PFCF -0.418
  • PE -1.4586
  • Debt/Assets 0.0167
  • DivYield 0
  • ROE -0.3413

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
OVID
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Neutral

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

Read More
image for news Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
OVID
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
OVID
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.

Read More
image for news Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

About Ovid Therapeutics Inc. (OVID)

  • IPO Date 2017-05-05
  • Website https://www.ovidrx.com
  • Industry Biotechnology
  • CEO Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
  • Employees 23
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.